Cancer · VITD-CANC-01 · v2
Borderline: within 4 points of the Doubtful/Refuted boundary, so a re-grade could land either side.
The biggest and most direct trials that asked exactly this question found no reduction in the number of people who developed cancer: VITAL [1] and the ViDA analysis [6] both landed essentially on no difference between vitamin D and placebo. A smaller trial [2] pointed in a hopeful direction but did not reach statistical significance and gave participants calcium alongside vitamin D, so the two cannot be separated. The one clearly positive finding [5] was for advanced (spreading or fatal) cancer, which is a different question from how many people get cancer in the first place. Studies of pre-cancerous colon growths showed either no effect [17] or a possible increase in risk [15]. Taken together the direct evidence points against the claim, while the scattered secondary signals stop it from being dismissed outright.
The two largest primary-prevention trials report no reduction in total cancer incidence: VITAL [1] hazard ratio 0.96 (95% CI, 0.88 to 1.06; P=0.47) and ViDA [6] adjusted hazard ratio 1.01 (95% CI, 0.81-1.25; P=.95). Lappe [2] found a new cancer diagnosis in 45 (3.89%) of the vitamin D3 + calcium group versus 64 (5.58%) of placebo, hazard ratio 0.70 (95% CI, 0.47 to 1.02) but P=.06 and with calcium co-administered. DO-HEALTH [20] gives a vitamin-D-alone hazard ratio of 0.76 (0.49-1.18), with significance only in combined arms, down to 0.39 (0.18-0.85) for all three treatments together. The positive signal in [5] is for advanced cancer, hazard ratio 0.83 (95% CI, 0.69-0.99; P=.04), and colorectal precursor endpoints show no association [17] (adenoma OR 1.08, 95% CI 0.92-1.27) or elevated serrated-polyp risk [15]. The contested point: The division is between outcome definitions: direct total-incidence endpoints are null [1][6], yet vitamin D is associated with fewer advanced (metastatic or fatal) cancers in [5] and with a non-significant point estimate below 1 in [2] and [20]. The panel treats the advanced-cancer and combination-arm signals as a different or confounded outcome rather than support for incidence reduction.
All 22 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Vitamin D, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The two largest and most direct RCTs for the exact claim — VITAL [1] (HR 0.96) and ViDA [6] (HR 1.01) — are squarely null for total cancer incidence, so the primary evidence contradicts rather than supports the claim.
Lappe [2] and Crockett [15] co-administer calcium with vitamin D; any effect cannot be attributed to vitamin D alone (confounded intervention).
Where it remains uncertain. The only significant benefit is for advanced (metastatic or fatal) cancer [5] (HR 0.83; 95% CI, 0.69-0.99), a different endpoint from incidence, and the suggestive incidence signal in [2] is confounded by co-administered calcium.
Aleatory
Combination-arm estimates in [20] rest on small counts (e.g. 4 vs 12 cases for all three treatments), so chance variation dominates.
Epistemic
Vitamin D is bundled with calcium in [2] and [15] and with omega-3 and exercise in [20], so a vitamin-D-specific effect on incidence cannot be isolated.
Inferential
The positive signal in [5] is advanced (metastatic or fatal) cancer, not incidence; generalising it to the incidence claim is an inferential leap.
The load-bearing papers from a corpus of 22, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Largest RCT; primary cancer-incidence endpoint null, directly against the claim.
“cancer was diagnosed in 1617 participants (793 in the vitamin D group and 824 in the placebo group; hazard ratio, 0.96; 95% confidence interval [CI], 0.88 to 1.06; P=0.47)”
Panel auditInternal validity: high · scope of inference: US men ≥50 and women ≥55 free of cancer at baseline, mostly vitamin D-replete, daily 2000 IU dosing.Key limitations: largely vitamin D-sufficient population · median follow-up only 5.3 years · fixed dose not titrated to deficiency
Non-significant for all-type cancer incidence; calcium co-intervention.
“supplementation with vitamin D3 and calcium compared with placebo did not result in a significantly lower risk of all-type cancer at 4 years”
Panel auditInternal validity: medium · scope of inference: Healthy postmenopausal women ≥55 in rural Nebraska with mean baseline 25(OH)D 32.8 ng/mL.Key limitations: calcium co-intervention confounds vitamin D effect · underpowered, borderline P=.06 · 4-year treatment duration
A positive signal, but for advanced/fatal cancer, not total incidence (same VITAL cohort as [1]).
“a significant reduction in advanced cancers (metastatic or fatal) was found for those randomized to vitamin D compared with placebo (226 of 12 927 assigned to vitamin D [1.7%] and 274 of 12 944 assigned to placebo [2.1%]; HR, 0.83 [95% CI, 0.69-0.99]; P = .04)”
Panel auditInternal validity: high · scope of inference: US adults ≥50/55; the signal is for advanced (metastatic or fatal) cancer and is strongest in normal-BMI individuals.Key limitations: total cancer incidence unchanged · secondary endpoint, subgroup-driven · advanced cancer is a subset not overall incidence
3 of 22 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct, high-quality RCT endpoints for cancer incidence are consistently null, so the claim is not carried by the evidence, though scattered secondary-endpoint and subgroup signals keep it from being fully refuted.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No deficiency-restricted incidence trial. Trials enrolled largely replete populations ([2] mean 25-OHD 32.8 ng/mL), yet [21] suggests effects concentrate in insufficient or deficient people. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A vitamin-D-alone primary-prevention RCT enrolling only vitamin-D-deficient adults with total cancer incidence as the pre-specified primary endpoint.
Open question: Does vitamin D alone reduce total cancer incidence in people who are genuinely vitamin-D-deficient? Why it is still open: The trials in the corpus enrolled mostly replete participants ([2] mean 25-OHD 32.8 ng/mL), and the emulation in [21] implies effects may be confined to insufficient or deficient populations.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19